SLC35D2

Summary

SLC35D2 (solute carrier family 35 member D2, HGNC:20799) is a protein-coding gene on chromosome 9q22.32, encoding Nucleotide sugar transporter SLC35D2 (Q76EJ3). Nucleotide sugar antiporter transporting UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-glucose (UDP-Glc) from the cytosol into the lumen of the Golgi in exchange of UMP. It is a selective cancer dependency (DepMap: 10.3% of cell lines).

Nucleotide sugars, which are synthesized in the cytosol or the nucleus, are high-energy donor substrates for glycosyltransferases located in the lumen of the endoplasmic reticulum and Golgi apparatus. Translocation of nucleotide sugars from the cytosol into the lumen compartment is mediated by specific nucleotide sugar transporters, such as SLC35D2 (Suda et al., 2004 [PubMed 15082721]).

Source: NCBI Gene 11046 — RefSeq curated summary.

At a glance

• GWAS associations: 12
• Clinical variants (ClinVar): 52 total
• Cancer dependency (DepMap): dependent in 10.3% of screened cell lines
• MANE Select transcript: NM_007001

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20799
Approved symbol	SLC35D2
Name	solute carrier family 35 member D2
Location	9q22.32
Locus type	gene with protein product
Status	Approved
Aliases	UGTrel8, SQV7L
Ensembl gene	ENSG00000130958
Ensembl biotype	protein_coding
OMIM	609182
Entrez	11046

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 19 protein_coding, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000253270, ENST00000375257, ENST00000375259, ENST00000482643, ENST00000490599, ENST00000650065, ENST00000878036, ENST00000878037, ENST00000878038, ENST00000878039, ENST00000878040, ENST00000878041, ENST00000878042, ENST00000923823, ENST00000923824, ENST00000923825, ENST00000955255, ENST00000955256, ENST00000955257, ENST00000955258, ENST00000955259

RefSeq mRNA: 2 — MANE Select: NM_007001 NM_001286990, NM_007001

CCDS: CCDS6717, CCDS69625

Canonical transcript exons

ENST00000253270 — 12 exons

Exon	Start	End
ENSE00000895689	96321998	96322080
ENSE00000895691	96336717	96336784
ENSE00000895692	96343904	96343996
ENSE00000895693	96345299	96345401
ENSE00000895694	96351103	96351171
ENSE00001466466	96320710	96321341
ENSE00001521249	96383477	96383711
ENSE00003482643	96368272	96368305
ENSE00003500446	96364464	96364550
ENSE00003563232	96324091	96324169
ENSE00003588009	96352038	96352109
ENSE00003608136	96360154	96360221

Expression profiles

Bgee: expression breadth ubiquitous, 277 present calls, max score 97.10.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 8.6400 / max 68.7528, expressed in 1689 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
101593	8.4558	1686
101592	0.1842	62

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
jejunal mucosa	UBERON:0000399	97.10	gold quality
mucosa of transverse colon	UBERON:0004991	95.97	gold quality
duodenum	UBERON:0002114	95.65	gold quality
rectum	UBERON:0001052	95.00	gold quality
endothelial cell	CL:0000115	94.05	gold quality
body of pancreas	UBERON:0001150	92.98	gold quality
islet of Langerhans	UBERON:0000006	92.94	gold quality
right lobe of liver	UBERON:0001114	92.88	gold quality
colonic mucosa	UBERON:0000317	92.57	gold quality
monocyte	CL:0000576	92.53	gold quality
palpebral conjunctiva	UBERON:0001812	92.46	gold quality
mononuclear cell	CL:0000842	92.40	gold quality
transverse colon	UBERON:0001157	92.38	gold quality
liver	UBERON:0002107	92.29	gold quality
pancreas	UBERON:0001264	92.22	gold quality
leukocyte	CL:0000738	92.19	gold quality
mucosa of stomach	UBERON:0001199	92.05	gold quality
secondary oocyte	CL:0000655	91.92	gold quality
small intestine Peyer’s patch	UBERON:0003454	91.80	gold quality
small intestine	UBERON:0002108	91.78	gold quality
mucosa of paranasal sinus	UBERON:0005030	91.47	gold quality
mucosa of sigmoid colon	UBERON:0004993	91.46	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	91.01	gold quality
body of stomach	UBERON:0001161	90.92	gold quality
buccal mucosa cell	CL:0002336	90.89	gold quality
nephron tubule	UBERON:0001231	90.80	gold quality
right lung	UBERON:0002167	90.74	gold quality
intestine	UBERON:0000160	90.70	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	90.69	gold quality
large intestine	UBERON:0000059	90.31	gold quality

Single-cell (SCXA)

Detected in 5 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.83
E-GEOD-111727	no	409.38
E-CURD-10	no	198.57
E-GEOD-124858	no	83.64
E-CURD-89	no	76.32

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting SLC35D2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4500	99.99	72.72	2367
HSA-LET-7A-5P	99.98	72.29	1790
HSA-LET-7B-5P	99.98	72.31	1790
HSA-LET-7C-5P	99.98	72.29	1790
HSA-LET-7E-5P	99.98	72.29	1790
HSA-LET-7F-5P	99.98	72.56	1784
HSA-LET-7G-5P	99.98	72.37	1784
HSA-LET-7I-5P	99.98	72.37	1788
HSA-MIR-98-5P	99.98	72.33	1787
HSA-MIR-8075	99.97	67.20	962
HSA-LET-7D-5P	99.96	71.76	1632
HSA-MIR-4458	99.96	71.64	1650
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-7-1-3P	99.91	71.53	4384
HSA-MIR-7-2-3P	99.91	71.40	4394
HSA-MIR-202-3P	99.84	71.41	1290
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-4699-3P	99.71	70.15	3142
HSA-MIR-548AU-3P	99.70	68.22	1373
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-5584-5P	99.49	68.22	2814
HSA-MIR-4735-5P	99.43	68.49	1780
HSA-MIR-208A-5P	99.42	70.83	1913
HSA-MIR-208B-5P	99.42	70.83	1952
HSA-MIR-4505	99.27	67.81	2678
HSA-MIR-5787	99.22	67.86	2628

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 10.3% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 2)

• HFRC1 takes part in the synthesis of heparan sulfate by regulating the level of UDP-GlcNAc, a donor substrate for the heparan sulfate synthases (PMID:15082721)
• HFRC1 was overexpressed in human bronchial epithelial cells and was shown to localize in the Golgi and to enhance the surface expression of N-acetylglucosamine-rich glycans. (PMID:19276090)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	slc35d2	ENSDARG00000089837
mus_musculus	Slc35d2	ENSMUSG00000033114
rattus_norvegicus	Slc35d2	ENSRNOG00000027229
drosophila_melanogaster	frc	FBGN0042641
caenorhabditis_elegans		WBGENE00005025

Paralogs (9): SLC35C2 (ENSG00000080189), SLC35E4 (ENSG00000100036), SLC35D1 (ENSG00000116704), SLC35E1 (ENSG00000127526), TMEM241 (ENSG00000134490), SLC35E3 (ENSG00000175782), SLC35C1 (ENSG00000181830), SLC35D3 (ENSG00000182747), SLC35E2B (ENSG00000189339)

Protein

Protein identifiers

Nucleotide sugar transporter SLC35D2 — Q76EJ3 (reviewed: Q76EJ3)

Alternative names: Homolog of Fringe connection protein 1, SQV7-like protein, Solute carrier family 35 member D2, UDP-galactose transporter-related protein 8

All UniProt accessions (4): Q76EJ3, A0A3B3ITR5, A0A3B3IU97, Q5VZJ2

UniProt curated annotations — full annotation on UniProt →

Function. Nucleotide sugar antiporter transporting UDP-N-acetylglucosamine (UDP-GlcNAc) and UDP-glucose (UDP-Glc) from the cytosol into the lumen of the Golgi in exchange of UMP. By supplying UDP-N-acetylglucosamine, a donor substrate to heparan sulfate synthases, probably takes part in the synthesis of these glycoconjugates.

Subcellular location. Golgi apparatus membrane.

Tissue specificity. Highly expressed in heart, kidney, small intestine, placenta, lung and peripheral blood leukocyte. Weakly expressed in skeletal muscle and spleen. Not expressed in brain, colon and thymus.

Similarity. Belongs to the TPT transporter family. SLC35D subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q76EJ3-1	1	yes
Q76EJ3-2	2

RefSeq proteins (2): NP_001273919, NP_008932* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR004853	Sugar_P_trans_dom	Domain
IPR050186	TPT_transporter	Family

Pfam: PF03151

Catalyzed reactions (Rhea), 2 shown:

• UMP(out) + UDP-N-acetyl-alpha-D-glucosamine(in) = UMP(in) + UDP-N-acetyl-alpha-D-glucosamine(out) (RHEA:72695)
• UMP(out) + UDP-alpha-D-glucose(in) = UMP(in) + UDP-alpha-D-glucose(out) (RHEA:72731)

UniProt features (19 total): topological domain 8, transmembrane region 8, chain 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q76EJ3-F1	85.58	0.63

Function

Pathways and Gene Ontology

Reactome pathways

15 pathways

ID	Pathway
R-HSA-173599	Formation of the active cofactor, UDP-glucuronate
R-HSA-2022854	Keratan sulfate biosynthesis
R-HSA-2022928	HS-GAG biosynthesis
R-HSA-727802	Transport of nucleotide sugars
R-HSA-1430728	Metabolism
R-HSA-156580	Phase II - Conjugation of compounds
R-HSA-156588	Glucuronidation
R-HSA-1630316	Glycosaminoglycan metabolism
R-HSA-1638074	Keratan sulfate/keratin metabolism
R-HSA-1638091	Heparan sulfate/heparin (HS-GAG) metabolism
R-HSA-211859	Biological oxidations
R-HSA-382551	Transport of small molecules
R-HSA-425397	Transport of vitamins, nucleosides, and related molecules
R-HSA-425407	SLC-mediated transmembrane transport
R-HSA-71387	Metabolism of carbohydrates and carbohydrate derivatives

MSigDB gene sets: 182 (showing top): GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_DN, GSE18804_SPLEEN_MACROPHAGE_VS_TUMORAL_MACROPHAGE_UP, GSE45365_NK_CELL_VS_CD8A_DC_DN, REACTOME_BIOLOGICAL_OXIDATIONS, FAELT_B_CLL_WITH_VH_REARRANGEMENTS_DN, GOBP_CARBOHYDRATE_DERIVATIVE_METABOLIC_PROCESS, GOBP_ORGANIC_ACID_TRANSPORT, GOBP_ORGANOPHOSPHATE_ESTER_TRANSPORT, GOBP_HEPARAN_SULFATE_PROTEOGLYCAN_METABOLIC_PROCESS, GOBP_CARBOHYDRATE_DERIVATIVE_BIOSYNTHETIC_PROCESS, KINSEY_TARGETS_OF_EWSR1_FLII_FUSION_DN, GOMF_NUCLEOBASE_CONTAINING_COMPOUND_TRANSMEMBRANE_TRANSPORTER_ACTIVITY, GOBP_NUCLEOBASE_CONTAINING_COMPOUND_TRANSPORT, GOBP_ORGANIC_ANION_TRANSPORT

GO Biological Process (6): heparan sulfate proteoglycan biosynthetic process (GO:0015012), nucleotide-sugar transmembrane transport (GO:0015780), UDP-glucuronate transmembrane transport (GO:0015787), UDP-N-acetylgalactosamine transmembrane transport (GO:0015789), keratan sulfate proteoglycan biosynthetic process (GO:0018146), UDP-N-acetylglucosamine transmembrane transport (GO:1990569)

GO Molecular Function (5): nucleotide-sugar transmembrane transporter activity (GO:0005338), UDP-glucuronate transmembrane transporter activity (GO:0005461), UDP-N-acetylglucosamine transmembrane transporter activity (GO:0005462), UDP-N-acetylgalactosamine transmembrane transporter activity (GO:0005463), antiporter activity (GO:0015297)

GO Cellular Component (3): Golgi membrane (GO:0000139), Golgi apparatus (GO:0005794), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-11 pathways:

Category	Pathways
Glycosaminoglycan metabolism	2
Metabolism	2
Glucuronidation	1
Keratan sulfate/keratin metabolism	1
Heparan sulfate/heparin (HS-GAG) metabolism	1
Transport of vitamins, nucleosides, and related molecules	1
Biological oxidations	1
Phase II - Conjugation of compounds	1
Metabolism of carbohydrates and carbohydrate derivatives	1
SLC-mediated transmembrane transport	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
pyrimidine nucleotide-sugar transmembrane transport	3
pyrimidine nucleotide-sugar transmembrane transporter activity	3
proteoglycan biosynthetic process	2
heparan sulfate proteoglycan metabolic process	1
protein O-linked glycosylation via xylose	1
organophosphate ester transport	1
nucleobase-containing compound transport	1
transmembrane transport	1
carbohydrate derivative transport	1
carboxylic acid transmembrane transport	1
keratan sulfate proteoglycan metabolic process	1
organophosphate ester transmembrane transporter activity	1
nucleobase-containing compound transmembrane transporter activity	1
carbohydrate derivative transmembrane transporter activity	1
UDP-glucuronate transmembrane transport	1
carboxylic acid transmembrane transporter activity	1
UDP-N-acetylglucosamine transmembrane transport	1
UDP-N-acetylgalactosamine transmembrane transport	1
secondary active transmembrane transporter activity	1
Golgi apparatus	1
bounding membrane of organelle	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
cellular anatomical structure	1

Protein interactions and networks

STRING

580 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SLC35D2	SLC35A3	Q9Y2D2	958
SLC35D2	SLC35A1	P78382	929
SLC35D2	SLC35B4	Q969S0	918
SLC35D2	SLC35B2	Q8TB61	828
SLC35D2	MAN2A2	P49641	824
SLC35D2	SLC35B3	Q9H1N7	813
SLC35D2	SLC35B1	P78383	770
SLC35D2	MAN2A1	Q16706	767
SLC35D2	ADGRL1	O94910	689
SLC35D2	B4GALT1	P15291	688
SLC35D2	SULT4A1	Q9BR01	681
SLC35D2	SLC35A2	P78381	661
SLC35D2	SLC35H1	Q9NQQ7	587
SLC35D2	SLC35A5	Q9BS91	576
SLC35D2	SLC35C1	Q96A29	520
SLC35D2	SLC35A4	Q96G79	520

IntAct

4 interactions, top by confidence:

A	B	Type	Score
NS3	C15orf61	psi-mi:“MI:0914”(association)	0.350
SLC35A4	PGRMC1	psi-mi:“MI:0914”(association)	0.350
SLC35D2	TM9SF1	psi-mi:“MI:0914”(association)	0.350

BioGRID (25): SLC35D2 (Affinity Capture-RNA), SLC35D2 (Affinity Capture-MS), ALG1 (Affinity Capture-MS), ASPH (Affinity Capture-MS), CAV1 (Affinity Capture-MS), ENDOD1 (Affinity Capture-MS), MARCH5 (Affinity Capture-MS), MICB (Affinity Capture-MS), MMS19 (Affinity Capture-MS), COX2 (Affinity Capture-MS), NPEPPS (Affinity Capture-MS), OTULIN (Affinity Capture-MS), RAB39A (Affinity Capture-MS), ROR1 (Affinity Capture-MS), ROR2 (Affinity Capture-MS)

ESM2 similar proteins: A2AKQ0, A2VE55, A5GFZ5, B8B7Q4, F4JN00, O14494, O42602, O60762, O70152, O75352, O88956, P0CK96, P60588, Q15B89, Q1JQ93, Q28HF8, Q2M3R5, Q3ZCD7, Q4L208, Q4R8V4, Q52KD1, Q5PT50, Q5PT53, Q5RDC9, Q5XF09, Q5ZJ75, Q5ZJH8, Q64232, Q6DBP3, Q6DHK8, Q6NMB6, Q6ZL17, Q762D5, Q76EJ3, Q7T0V6, Q8C811, Q8GUJ1, Q8IVW8, Q8R4D1, Q8RXL8

Diamond homologs: A2AKQ0, A2VE55, A8MRY9, Q15B89, Q18779, Q54YK1, Q5RDC9, Q762D5, Q76EJ3, Q95YI5, Q9NTN3, Q94B65

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

52 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2157 predictions. Top by Δscore:

Variant	Effect	Δscore
9:96324086:CTCA:C	donor_loss	1.0000
9:96324087:TCAC:T	donor_loss	1.0000
9:96324088:CACCT:C	donor_loss	1.0000
9:96343898:GCTCA:G	donor_loss	1.0000
9:96343899:CTCA:C	donor_loss	1.0000
9:96343900:TCACC:T	donor_loss	1.0000
9:96343901:CACCT:C	donor_loss	1.0000
9:96343902:ACC:A	donor_loss	1.0000
9:96343903:C:CT	donor_loss	1.0000
9:96351102:CCCAG:C	donor_gain	1.0000
9:96364458:ACTT:A	donor_loss	1.0000
9:96364459:CTT:C	donor_loss	1.0000
9:96364460:TTA:T	donor_loss	1.0000
9:96364461:TAC:T	donor_loss	1.0000
9:96364462:A:AT	donor_loss	1.0000
9:96364463:C:A	donor_loss	1.0000
9:96364550:TCT:T	acceptor_loss	1.0000
9:96364551:C:CC	acceptor_gain	1.0000
9:96364551:C:CG	acceptor_loss	1.0000
9:96364552:T:G	acceptor_loss	1.0000
9:96368306:C:CC	acceptor_gain	1.0000
9:96383471:CCTCA:C	donor_loss	1.0000
9:96383472:CTCAC:C	donor_loss	1.0000
9:96383473:TCA:T	donor_loss	1.0000
9:96383474:CA:C	donor_loss	1.0000
9:96383475:AC:A	donor_gain	1.0000
9:96383476:C:G	donor_loss	1.0000
9:96383476:CC:C	donor_gain	1.0000
9:96322077:CATT:C	acceptor_gain	0.9900
9:96324166:AAAC:A	acceptor_loss	0.9900

AlphaMissense

2181 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:96352085:C:A	R124S	0.995
9:96352085:C:G	R124S	0.995
9:96324091:C:A	K277N	0.994
9:96324091:C:G	K277N	0.994
9:96324139:G:C	C261W	0.994
9:96352086:C:G	R124T	0.994
9:96360168:G:C	S111R	0.994
9:96360168:G:T	S111R	0.994
9:96360170:T:G	S111R	0.994
9:96324141:A:G	C261R	0.993
9:96351122:C:G	G157R	0.993
9:96351122:C:T	G157R	0.993
9:96351141:A:C	S150R	0.993
9:96351141:A:T	S150R	0.993
9:96351143:T:G	S150R	0.993
9:96351121:C:T	G157E	0.992
9:96345339:G:T	A184E	0.991
9:96345340:C:G	A184P	0.991
9:96322010:C:T	G301E	0.990
9:96322011:C:G	G301R	0.990
9:96322011:C:T	G301R	0.990
9:96324127:A:C	N265K	0.990
9:96324127:A:T	N265K	0.990
9:96352086:C:A	R124M	0.990
9:96336718:C:G	G251R	0.989
9:96336718:C:T	G251R	0.989
9:96345337:C:G	A185P	0.989
9:96351122:C:A	G157W	0.989
9:96345376:C:G	G172R	0.988
9:96368302:G:C	F54L	0.988

dbSNP variants (sampled 300 via entrez): RS1000045802 (9:96315437 T>C,G), RS1000159661 (9:96318708 G>A), RS1000175627 (9:96331412 A>C,G), RS1000195011 (9:96358801 C>A), RS1000264375 (9:96365396 C>T), RS1000302090 (9:96374763 G>A,T), RS1000358259 (9:96372493 A>C), RS1000368162 (9:96372297 A>G), RS1000387581 (9:96353415 G>A), RS1000422276 (9:96371996 G>A,T), RS1000432149 (9:96381366 C>T), RS1000449636 (9:96352659 T>G), RS1000533851 (9:96357536 T>A,C), RS1000547991 (9:96349854 A>G), RS1000548848 (9:96363873 C>T)

Disease associations

OMIM: gene MIM:609182 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

12 associations (top):

Study	Trait	p-value
GCST001734_13	Non-small cell lung cancer	9.000000e-06
GCST004067_121	Hip circumference adjusted for BMI	2.000000e-08
GCST004067_53	Hip circumference adjusted for BMI	5.000000e-09
GCST004599_74	Mean platelet volume	3.000000e-13
GCST005991_96	Platelet count	4.000000e-12
GCST008163_364	Height	2.000000e-09
GCST009391_38	Metabolite levels	7.000000e-06
GCST012227_437	Hip circumference adjusted for BMI	3.000000e-12
GCST012227_438	Hip circumference adjusted for BMI	9.000000e-10
GCST012227_439	Hip circumference adjusted for BMI	4.000000e-08
GCST90002390_392	Mean corpuscular hemoglobin	2.000000e-11
GCST90002391_244	Mean corpuscular hemoglobin concentration	1.000000e-09

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0008039	BMI-adjusted hip circumference
EFO:0004309	platelet count
EFO:0010116	choline measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0004528	mean corpuscular hemoglobin concentration

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — SLC35 family of nucleotide sugar transporters

CTD chemical–gene interactions

33 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
Tobacco Smoke Pollution	decreases reaction, increases expression, increases reaction, affects expression	2
Cyclosporine	increases expression, decreases expression	2
methylmercuric chloride	decreases expression	1
cinnamaldehyde	decreases expression	1
sodium arsenite	increases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
aflatoxin B2	decreases methylation	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	decreases expression, affects cotreatment	1
vanillin	decreases expression	1
3-iodothyronamine	affects uptake	1
ICG 001	increases expression	1
abrine	decreases expression	1
bisphenol S	affects cotreatment, increases methylation	1
(+)-JQ1 compound	decreases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Vorinostat	decreases expression	1
Acetaminophen	decreases expression	1
Acetylcysteine	decreases reaction, increases expression	1
Air Pollutants	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Cadmium	increases expression, increases response to substance	1
Carbamazepine	affects expression	1
Coumestrol	affects cotreatment, decreases expression	1
Doxorubicin	affects expression	1
Lead	increases expression	1
Vanadates	decreases expression	1

Cellosaurus cell lines

4 cell lines: 4 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_D4TA	HuH7-SLC35D2-KO-c3	Cancer cell line	Male
CVCL_D4TB	HuH7-SLC35D2-KO-c4	Cancer cell line	Male
CVCL_TN18	HAP1 SLC35D2 (-) 1	Cancer cell line	Male
CVCL_XT23	HAP1 SLC35D2 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.